|Bid||8.62 x 200|
|Ask||8.64 x 100|
|Day's range||8.47 - 8.87|
|52-week range||8.47 - 36.21|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.14|
Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.
Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.
Acne is an enticing, if not particularly lifesaving, market for drugmakers, with more than $3 billion in revenue at stake.
Dermira crashed more than 60% early Monday after announcing a pair of acne trials failed in Phase 3 testing.
U.S. stocks swung higher on Monday as investors said they were expecting U.S. President Donald Trump to back down on his threat to impose hefty tariffs on steel and aluminum imports. The three major U.S. equity indexes rose on bets the threat was just a negotiating tool after Trump said Canada and Mexico could avoid his proposed tariffs if they ceded ground on the North American Free Trade Agreement. Also U.S. House Speaker Paul Ryan urged the administration not to move forward on the tariffs, citing risks to the economy.
Dermira Inc. shares plummeted 70% in premarket trade Monday after the company's acne drug failed to meet the co-primary endpoints of two phase 3 clinical trials. The company expects to discontinue development ...
The Menlo Park, California-based company said it had a loss of $1.34 per share. The skin condition drug developer posted revenue of $1.3 million in the period. For the year, the company reported that its ...
The Menlo Park, California-based company said it had a loss of $4.30 per share. Losses, adjusted for costs related to mergers and acquisitions, came to $1.21 per share. The skin condition drug developer ...